Source: International Congress 2017 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Dransfield (Birmingham, United States of America). Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes. 1069

Member's Comments

No comment yet.

Related content which might interest you: Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study Source: International Congress 2017 – Management of COPD Year: 2017 Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Evaluation of adherence of patients with asthma to treatment by single combination inhaler Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002 Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations? Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Influence of treatment by single combined inhaler on adherence of patients with asthma Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Symptomatic burden of COPD for patients receiving dual or triple therapy Source: International Congress 2017 – Management of COPD Year: 2017 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019